Search
Biospace news
RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)
Updated: 7 hours 20 min ago
PhRMA Loses Another Legal Battle as Court Sides with Arkansas Over Drug Discount Program
PhRMA Loses Another Legal Battle as Court Sides with Arkansas Over Drug Discount Program 3/14/2024
The Unintended Consequences of Small Molecules
The Unintended Consequences of Small Molecules 3/14/2024
Biden, Sanders Target Drug Prices at White House Event
Biden, Sanders Target Drug Prices at White House Event 4/3/2024
Genmab Leans into Hot ADC Space with $1.8B ProfoundBio Acquisition
Genmab Leans into Hot ADC Space with $1.8B ProfoundBio Acquisition 4/3/2024
Vanda Gets FDA Approval for Fanapt Antipsychotic, Expands into Bipolar Disorder
Vanda Gets FDA Approval for Fanapt Antipsychotic, Expands into Bipolar Disorder 4/3/2024
Diagonal Therapeutics Nets $128M for New Approach to Agonist Antibodies
Diagonal Therapeutics Nets $128M for New Approach to Agonist Antibodies 4/3/2024
Four Doses of Lilly’s Mounjaro Will Be in Short Supply Through April 2024: FDA
Four Doses of Lilly’s Mounjaro Will Be in Short Supply Through April 2024: FDA 4/3/2024
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo 4/3/2024
Acorda Joins Growing Group of Biotechs Filing for Bankruptcy, Divests Assets to Merz
Acorda Joins Growing Group of Biotechs Filing for Bankruptcy, Divests Assets to Merz 4/3/2024
Chinese ADC Investment Boom in Question With China-U.S. R&D Relations in Flux
Chinese ADC Investment Boom in Question With China-U.S. R&D Relations in Flux 4/3/2024
Opinion: Slow Down on IRA Expansions, Research Possible Outcomes
Opinion: Slow Down on IRA Expansions, Research Possible Outcomes 4/3/2024
Flush With New $150M Investment, Avenzo Pursues Licensing Strategy
Flush With New $150M Investment, Avenzo Pursues Licensing Strategy 4/3/2024
C-Suite Shuffle: Lonza Hires New CEO
C-Suite Shuffle: Lonza Hires New CEO 4/3/2024
Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns
Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns 4/2/2024
Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC
Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC 4/2/2024
Vertex Pushes Oral Drug into Phase III Kidney Disease Trial, Eyes Accelerated Approval
Vertex Pushes Oral Drug into Phase III Kidney Disease Trial, Eyes Accelerated Approval 4/2/2024
Roivant Posts Phase II Eye Disease Win for TYK2 Drug, Plans Pivotal Program
Roivant Posts Phase II Eye Disease Win for TYK2 Drug, Plans Pivotal Program 4/2/2024
Teva, Viatris Again Challenge J&J Patent for Schizophrenia Drug with Appeals Court Win
Teva, Viatris Again Challenge J&J Patent for Schizophrenia Drug with Appeals Court Win 4/2/2024
Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year
Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year 4/2/2024
Gritstone Fails Cancer Vaccine Trial, Plans Phase III and Public Offering
Gritstone Fails Cancer Vaccine Trial, Plans Phase III and Public Offering 4/2/2024
World Pharma News
- AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease
- Next-generation treatments hitch a ride into cancer cells
- Groundbreaking treatment approach shows promise in hard-to-treat cancers
- This outdated diabetes drug still has something to offer
- New drug prevents flu-related inflammation and lung damage